Home
National Institute for Health Research Biomedical Research Centre
Our Research: Biomarker Platforms

Genomics

With our strong track record of collaborative genetics and genomics expertise, Greater Manchester has a reputation for pioneering discoveries and developing new tests that are used clinically within the NHS.

Central Manchester University Hospitals NHS Foundation Trust (CMFT) hosts one of the largest integrated genetics facilities in Europe, employing over 250 staff, and has a national molecular testing role for over 50 services. We have a wealth of experience in applying Next Generation Sequencing, real time polymerase chain reaction (PCR), reverse transcriptase PCR, circulating tumour DNA (ctDNA), Sanger sequencing and bioinformatics techniques to DNA based biomarker studies.

Our genomics expertise will work across research themes to drive further P4 Medicine test development, for example:

  • Genetic markers in adult inflammatory arthritis to prevent development of rheumatoid arthritis and psoriatic arthritis
  • Genetic predictors of hearing loss
  • ctDNA for personalised monitoring and treatment planning in cancer
  • Tumour genomic profiles to predict benefit from proton beam therapy versus photon therapies